Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 80,000 Shares

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler purchased 80,000 shares of the company’s stock in a transaction on Friday, January 23rd. The shares were purchased at an average price of $11.81 per share, with a total value of $944,800.00. Following the completion of the purchase, the director directly owned 1,543,210 shares of the company’s stock, valued at $18,225,310.10. The trade was a 5.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Biodesix Stock Up 10.2%

Shares of NASDAQ BDSX traded up $1.03 during trading on Tuesday, reaching $11.12. 67,524 shares of the stock were exchanged, compared to its average volume of 4,904,886. The business’s 50-day moving average price is $7.67 and its 200 day moving average price is $7.69. The company has a market capitalization of $88.48 million, a price-to-earnings ratio of -2.00 and a beta of 0.60. Biodesix, Inc. has a twelve month low of $3.44 and a twelve month high of $21.60. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 41.11.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.60) by $0.44. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%.The company had revenue of $21.77 million for the quarter, compared to the consensus estimate of $20.98 million. As a group, equities analysts forecast that Biodesix, Inc. will post -0.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on BDSX. Wall Street Zen raised Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodesix in a report on Monday, December 22nd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Biodesix currently has a consensus rating of “Moderate Buy” and an average price target of $32.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC bought a new position in shares of Biodesix during the 3rd quarter worth approximately $113,000. Oracle Investment Management Inc. purchased a new stake in Biodesix during the 3rd quarter worth about $113,000. XTX Topco Ltd boosted its position in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after acquiring an additional 102,494 shares during the period. Finally, Aberdeen Group plc purchased a new position in shares of Biodesix during the 4th quarter valued at $1,784,000. 20.96% of the stock is owned by institutional investors and hedge funds.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.